from Jules: At EASL results were reported for ALLY-1/2/3, the phase 3 clinical trials program for daclatasvir, approval by the FDA for Gt3 is expected around August, PDUFA date [http://www.natap.org/2015/HCV/031615_07.htm]. As well below are a number of European cohort studies examining daclatasvir/sofosbuvir. Of note is the French liver transplant study below from Audrey Coilly and the Compassionate Use Program results.
